Mylan Ups Investment In Mapi’s Monthly Glatiramer
Puts Another $20m Into Candidate Undergoing Phase III Trials
Executive Summary
Mylan has invested a further $20m in a monthly glatiramer acetate depot product being developed by partner Mapi for submission via the 505(b)(2) route in the US.